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Scope: Flavonoids are generally studied in vitro, in isolation, and as unmetabolized precursor
structures. However, in the habitual diet, multiple flavonoids are consumed together and found
present in the circulation as complex mixtures of metabolites. Using a unique study design,
we investigated the potential for singular or additive anti-inflammatory effects of flavonoid
metabolites relative to their precursor structures.
Methods and results: Six flavonoids, 14 flavonoid metabolites, and 29 combinations of
flavonoids and their metabolites (0.1–10 M) were screened for their ability to reduce LPS-
induced tumor necrosis factor- (TNF-) secretion in THP-1 monocytes. One micromo-
lar peonidin-3-glucoside, cyanidin-3-glucoside, and the metabolites isovanillic acid (IVA),
IVA-glucuronide, vanillic acid-glucuronide, protocatechuic acid-3-sulfate, and benzoic acid-
sulfate significantly reduced TNF- secretion when in isolation, while there was no effect on
TNF- mRNA expression. Four combinations of metabolites that included 4-hydroxybenzoic
acid (4HBA) and/or protocatechuic acid also significantly reduced TNF- secretion to a greater
extent than the precursors or metabolites alone. The effects on LPS-induced IL-1 and IL-10 se-
cretion andmRNA expression were also examined. 4HBA significantly reduced IL-1 secretion
but none of the flavonoids or metabolites significantly modified IL-10 secretion.
Conclusion: This study provides novel evidence suggesting flavonoid bioactivity results from
cumulative or additive effects of circulating metabolites.
Keywords:
Cytokine / Inflammation / Metabolism / Phase 2 conjugates / Polyphenol
 Additional supporting information may be found in the online version of this article atthe publisher’s web-site
1 Introduction
Flavonoids are phenolic secondary plant metabolites found
ubiquitously in our habitual diets [1, 2]. They have been ex-
tensively studied due to the widely held hypothesis that they
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contribute to the positive health effects associated with fruit
and vegetable consumption [3]. Flavonoid consumption has
been associated with a lower incidence of chronic age re-
lated diseases, including cardiovascular disease, cancer, and
neurodegenerative disorders [3–5], where chronic low grade
inflammation is a central underlying predisposing risk factor
[6]. Tumor necrosis factor-alpha (TNF-) and IL-1 are cen-
tral mediators of the inflammatory process and pharmaco-
logical inhibition of these pro-inflammatory cytokines results
in improved cardiovascular health and a lower incidence of
myocardial infarction [7, 8]. Flavonoids have been shown to
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reduce TNF- and IL-1 levels in human and animal stud-
ies and cell culture models [9–11]. In addition, IL-10 plays
an important anti-inflammatory role in the resolution of in-
flammation and has been shown to be upregulated by sev-
eral flavonoids including hesperidin, quercetin, and catechin
[12, 13]. TNF-, IL-1, and IL-10 are all regulated by the pro-
inflammatory transcription factor nuclear factor kappa-light-
chain-enhancer of activated B cells (NF-B), and NF-B has
also been shown to be a target of several flavonoids including
quercetin [14] and cyanidin-3-glucoside (C3G) [15].
Most in vitro studies conducted to date have focused on the
effect of individual precursor flavonoids on inflammatoryme-
diators [16]. However, flavonoids are extensively metabolized
and found in the systemic circulation as phase II conjugates
or products of bacterial catabolism [17,18]. It is thereforemore
relevant to study the effects of flavonoid metabolites (Fig. 1)
over their precursor unmetabolized structures [19]. Similarly,
previous studies have focused on supraphysiological concen-
trations of flavonoids in in vitro studies using doses often
between 25 and 100 M [16]. Therefore, it is equally impor-
tant to consider physiologically appropriate concentrations
of flavonoid metabolites, as most are unlikely to reach lev-
els in excess of 10 M in the human systemic circulation
[20]. Lastly, in the habitual diet, flavonoids are consumed
as complex mixtures of compounds, which are consequently
present in the systemic circulation as diverse mixtures of pre-
cursor and metabolic conjugates. It is therefore important to
consider the potential for additive, synergistic, or inhibitory
effects of multiple compounds collectively. Here, we have
designed a study to address these previous conceptual inac-
curacies and attempted to explore the activities of flavonoid
metabolites at physiologically relevant concentrations and in
complex mixtures as they may be found in vivo.
In the present study, human THP-1 monocytic cells were
utilized (as previously described [21]) as an in vitro screening
model of inflammation, to explore the activity of flavonoid
metabolites on LPS-induced TNF-, IL-1, and IL-10 expres-
sion. Here, six common dietary flavonoids (quercetin, narin-
genin, epicatechin, hesperetin, peonidin-3-glucoside (P3G),
C3G), 14 metabolites (including synthesized methyl, glu-
curonide, and sulfate conjugates), and 29 unique combina-
tions of flavonoid andmetabolite were investigated. The treat-
ments were explored across concentrations ranging from 0.1
to 10 M (Table 1) in order to investigate the effects of more
physiologically relevant concentrations of flavonoids and their
metabolites [17, 19, 22, 23], as would be potentially found in
the circulation following the consumption of a flavonoid-rich
diet.
2 Materials and methods
2.1 Chemicals
The flavonoids hesperetin, naringenin, quercetin, epicat-
echin, C3G, and metabolites protocatechuic acid (PCA),
isovanillic acid (IVA), vanillic acid (VA), and 4-
hydroxybenzoic acid (4HBA) were obtained from Sigma
Aldrich (Poole, UK). P3G was obtained from Polyphe-
nols Laboratories AS (Sandes, Norway). The remaining
metabolites (benzoic acid (BA)-glucuronide, BA-sulfate, PCA-
3-glucuronide, PCA-4-glucuronide, PCA-3-sulfate, PCA-4-
sulfate, IVA-glucuronide, IVA-sulfate, VA-glucuronide, and
VA-sulfate) were not commercially available and synthesized
for the present study, as previously described [24]. Flavonoids
and their metabolites were dissolved in DMSO and added to
the cells at a final concentration of 0.1% DMSO. Treatments
containing mixtures of flavonoids or metabolites represented
cumulative concentrations of 0.1, 1, 10, or 100 M, where
each component provided an equal molar concentration. For
example, a 0.1 M treatment combination comprising three
components contained 0.033 M of each component, or
0.33 M of each component for a 1 M treatment, or 3.3 M
of each component for a 10M, and similarly 33.3M for the
100 M treatment. Escherichia coli LPS 5 mg/mL (O111:B4)
was obtained from Calbiochem (San Diego, USA). SB203580
was obtained from Tocris Bioscience (Bristol, UK). DMSO
and all other reagents were from Sigma, unless otherwise
indicated.
2.2 Cell culture
The human monocytic cell line, THP-1, was obtained from
the European Collection of Cell Cultures (Health Protec-
tion Agency, Salisbury, UK) and cultured in RPMI 1640
medium (PAA Laboratories, Pasching, Austria), supple-
mented with 10% fetal bovine serum (Sigma), 2 mM L-
glutamine, 100 U/mL penicillin, and 100 g/mL strepto-
mycin (PAA Laboratories) as previously described [25]. Cells
were maintained in culture at 37C in a humidified atmo-
spherewith 5%CO2. Cell densitywasmaintained between 0.3
and 0.8 × 106 cells/mL and used between passages 5 and 20.
2.3 Cell viability assay
Cell viability was measured using the WST-1 assay ac-
cording to the manufacturer’s protocol (Roche Diagnostics,
Mannheim, Germany). Briefly, 0.5 × 105 cells/well were
seeded in 96-well plates. Treatments were added at final con-
centrations of 5, 10, 50, and 100 M. Cells were incubated
for 24 h at 37C and 5% CO2. A total of 10 L WST-1 Cell
Proliferation Reagent was added for 3 h and absorbance was
measured at 450 nm.
2.4 Cytokine protein secretion
THP-1 cells (0.5 × 106 cells/well) were seeded in 24-well
plates. Treatments were added at final concentrations of 0.1,
1, 10, and 100 M. Plates were incubated at 37C, 5% CO2
for 30 min prior to addition of LPS. For TNF- production,
cells were stimulated with LPS (100 pg/mL) for 3 h. Cells
C© 2015 The Authors. Molecular Nutrition & Food Research published by Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim www.mnf-journal.com
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Figure 1. Structures of the six precursor flavonoids and their metabolites. Details of constituent groups given in inset table. –OGlc
represents an oxygen-linked glucose; –OGlcA represents an oxygen-linked glucuronide.
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were stimulated with 1 g/mL LPS for 24 h for IL-1 and
IL-10 production assays. Cytokine concentrations in super-
natants were quantified using human ELISA kits from BD
Biosciences (Oxford, UK). ELISAs were carried out in accor-
dance to the manufacturer’s instructions. Briefly, 100 L of
supernatant sample or standard in duplicate was incubated
for 2 h at room temperature on 96-well plates precoated with
an appropriate anti-human monoclonal antibody. Following
incubation, plates were washed in PBS/0.05% Tween-20. Im-
mediately following washing, 100 L of enzyme-linked sec-
ondary antibody was added to each well and incubated for 1 h
at room temperature. Plates were washed, 100L of substrate
solution was added to each well, and incubated for 30 min,
followed by the addition of 50L 1MH2SO4. Absorbance was
determined at 450 nm. The interassay coefficients of varia-
tion were 9.9, 7.8, and 5.7% for the TNF-, IL-1, and IL-10
ELISAs, respectively.
2.5 Cytokine mRNA expression
THP-1 cells (1 × 106 cells/mL) were treated with 1 M com-
pounds for 30 min prior to stimulation with LPS. After in-
cubation with 100 pg/mL LPS for 2 h (TNF-) or 1 g/mL
LPS for 24 h (IL-1), cells were centrifuged and the pellet was
resuspended in TRIzol Reagent (Ambion, Carlsbad, USA)
and total RNA was extracted according to the manufacturer’s
instructions. RNA concentration was quantified using a Nan-
odrop ND-1000 spectrophotometer and concentrations were
adjusted to 200 ng/L. RNA was reverse transcribed using
a TaqMan kit (Roche Diagnostics) according to the manu-
facturer’s instructions. Reverse transcription was carried out
on a PTC-100 thermocycler (Bio-Rad, Herts, UK) using the
following conditions: 21C for 10 min, 42C for 15 min,
99C for 5 min, and 4C for 5 min. Primers were obtained
from Invitrogen (Paisley, UK) with the following sequences:
TNF- forward: 5′-GCCCAGGCAGTCAGATCATC5-3′, re-
verse: 5′-CGGTTCAGCCACTGGAGCT-3′; IL-1 forward:
5′-GGACAAGCTGAGGAAGATGC-3′, reverse: 5′-TCGTTA
TCCCATGTGTCGAA-3′, and GAPDH forward: 5′-AACA
GCCTCAAGATCATCAGCA-3′, reverse: 5′-TGCTAAGCAGT
TGGTGGTGC-3′. mRNA expression was measured by real-
time PCR using a QIAGEN Rotor-Gene Q and SYBR Green
technology. DNA was replicated for 1 cycle of 95C for 120 s,
and then 40 cycles of 95C for 15 s and 40C for 40 s. Each
mRNA expression was normalized against GAPDH mRNA
expression using the standard curve method.
2.6 NF-B luciferase reporter assay
NF-B pGL3 firefly luciferase and pGL4.73 Renilla luciferase
plasmids and the Dual-Glo Luciferase assay were purchased
from Promega (Madison, USA). One milliliter of THP-1 cells
at 1 × 106 cells/mL were seeded in 24-well plates in RPMI
1640 medium. After 24 h, cells were transfected using Lipo-
fectamine LTX Plus reagent and Opti-MEM reduced serum
media (Invitrogen) according to the manufacturer’s protocol
and as previously described [26]. Cells were transfected with
pGL4.73 or pGL3 for 18 h. Cells were treated with 10 M
compounds for 30 min prior to LPS stimulation (100 ng/mL)
for 7 h at 37C, 5%CO2. Reporter activity wasmeasured using
the Dual-Glo luciferase assay on a BMG Labtech POLARstar
OPTIMA plate reader. Each firefly reading was normalized to
the corresponding Renilla reading prior to analysis.
2.7 Statistics
Data are presented as mean ± SD, from three indepen-
dent biological replicates. Treatments were compared to 0.1%
DMSO vehicle control (VC). One-way ANOVA with post-hoc
LSD (when comparing more than two conditions), or a two-
tailed independent sample t-test (when comparing two con-
ditions) was performed using PASW statistics 18 software
(Chicago, USA); *p < 0.05, **p < 0.01, ***p < 0.001.
3 Results
3.1 Effects of flavonoids and their metabolites on
cell viability
Flavonoids have previously been reported to affect cell viabil-
ity at high concentrations [27]. To ensure that the effects of the
treatments in the present study were not influenced by cell
viability, THP-1 cells were treated with 5–100 M flavonoid
for 24 h and cell viability was measured by WST-1 assay. No
flavonoid or metabolite was found to affect cell viability, in-
dividually or in combination, at 5, 10, or 50 M (data not
shown). Quercetin and naringenin were the only compounds
to significantly reduce cell viability at 100 M (16.2 ± 7.6%,
p < 0.001 and 13.2 ± 10.7%, p < 0.001; respectively).
3.2 Flavonoid metabolites inhibit TNF- secretion
Of the 20 individual compounds and 29 combination
treatments screened, two flavonoids, five metabolites, and
four combinations significantly reduced LPS-induced TNF-
protein levels compared to VC (Table 2). Specifically, treat-
ment with the precursor flavonoids C3G and P3G (reduction
13–20%; p  0.050), and the metabolites BA-sulfate, IVA,
IVA-glucuronide, VA-glucuronide, and PCA-3-sulfate (reduc-
tion 27–41%; p  0.040), significantly reduced LPS-induced
TNF- secretion. Of the combination treatments tested,
treatments containing PCA and 4HBA (combination 9); PCA,
VA, and 4HBA (combination 10); 4HBA, BA-glucuronide,
and BA-sulfate (combination 13); and PCA and PCA-3-
glucuronide (combination 16) significantly reduced TNF-
secretion (reduction of 4–47%; p  0.050). The individual
constituents of the active combination treatments were also
assessed and did not significantly reduce TNF- compared
to the VC at any concentration tested, up to and including
100 M (Fig. 2).
C© 2015 The Authors. Molecular Nutrition & Food Research published by Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim www.mnf-journal.com
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Table 2. Significant effects of treatments on LPS-induced TNF- protein secretion
Treatment Average change in TNF- protein from VC (% ± SD)
0.1 M 1 M 10 M
C3G ↓ 9.5 ± 2.4 ↓ 13.7 ± 4.4* ↓ 12.2 ± 1.2
P3G ↓ 12.7 ± 4.2* ↓ 19.8 ± 3.1*** ↓ 13.4 ± 6.5*
IVA ↓ 12.8 ± 3.3 ↓ 27.0 ± 3.5* ↓ 20.2 ± 5.7
BA-sulfate ↓ 24.9 ± 32.5 ↓ 37.2 ± 40.1* ↓ 27.3 ± 38.5
PCA-3-sulfate ↓ 24.6 ± 33.8 ↓ 41.1 ± 42.0* ↓ 38.6 ± 43.0*
IVA-glucuronide ↓ 16.8 ± 15.1* ↓ 32.8 ± 9.8*** ↓ 33.3 ± 11.8***
VA-glucuronide ↓ 12.5 ± 15.7 ↓ 26.9 ± 19.4* ↓ 26.8 ± 4.9*
Combination 9 ↓ 26.3 ± 6.4* ↓ 33.1 ± 6.1** ↓ 42.7 ± 13.5***
Combination 10 ↓ 17.9 ± 9.8 ↓ 47.4 ± 12.3** ↓ 35.1 ± 5.1**
Combination 13 ↓ 10.3 ± 29.0 ↓ 26.2 ± 37.6 ↓ 32.0 ± 35.4*
Combination 16 ↓ 1.1 ± 19.0 ↓ 6.5 ± 21.1* ↓ 4.4 ± 13.4*
Treatments (see Table 1 for details) were added to THP-1 cells at final concentrations of 0.1, 1, and 10 M for 30 min prior to stimulation
with 100 pg/mL LPS for 3 h. LPS-induced TNF- protein secretion was quantified by ELISA. Data shown are averages of three independent
experiments, each carried out in technical duplicate. Analysis was performed by one-way ANOVA and post-hoc LSD, *p < 0.05, **p < 0.01,
***p  0.001.
Figure 2. Effect of flavonoid treatments on LPS-induced THP-1 TNF- protein secretion. (A) C3G, (B) P3G, (C) IVA, (D) BA-sulfate,
(E) PCA-3-sulfate, (F) IVA-glucuronide, (G) VA-glucuronide, (H) Combination 9, (I) Combination 10, (J) Combination 13, (K) Combination 16,
(L) PCA, (M) 4HBA, (N) VA, (O) BA-glucuronide, and (P) PCA-3-glucuronide. Data were normalized to an LPS control and then compared
to VC. Columns represent mean ± SD (n = 3). Each independent experiment was carried out in technical duplicate. *p < 0.05, **p < 0.01,
***p < 0.001 (one-way ANOVA and post-hoc LSD).
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Table 3. Effect of treatments on IL-1 protein expression
Treatment Average change in IL-1
protein from vehicle
control (% ± SD)
1 M
C3G ↓ 1.3 ± 28.9
P3G ↓ 15.2 ± 20.6
IVA ↑ 19.2 ± 10.2
IVA-glucuronide ↑ 24.3 ± 15.3
VA-glucuronide ↓ 1.7 ± 50.3
PCA-3-sulfate ↓ 31.2 ± 3.6
BA-sulfate ↓ 28.9 ± 35.0
Combo 9 ↓ 8.7 ± 17.8
Combo 10 ↑ 15.5 ± 30.9
Combo 13 ↓ 6.0 ± 11.7
Combo 16 ↓ 10.3 ± 22.3
VA ↓ 23.0 ± 44.4
PCA ↓ 16.8 ± 15.0
4HBA ↓ 49.6 ± 12.3*
BA-glucuronide ↓ 2.6 ± 10.5
PCA-3-glucuronide ↓ 2.0 ± 22.1
Treatments were added to THP-1 cells at a final concentration of
1 M for 30 min prior to stimulation with 10 g/mL LPS for 24 h.
Data were normalized to LPS and compared with VC. Data shown
are averages of three independent experiments, each carried out
in technical duplicate. Analysis was performed by two-tailed in-
dependent samples t-test, *p < 0.05.
3.3 Effects of flavonoids on LPS-induced
NF-B-driven gene transcription
Flavonoids have previously been reported to inhibit NF-B
[28, 29], which is a major regulator of TNF-. To determine
if the flavonoids or metabolites also reduced other NF-B-
regulated cytokines, the bioactive treatments identified in the
TNF- screen were investigated for effects on IL-1 and IL-10
secretion.Here, none of the active treatments significantly in-
hibited LPS-induced IL-1 secretion (Table 3). Interestingly,
4HBA, a component of combination 9 and 10, significantly
reduced IL-1 protein secretion (49.6 ± 12.3% versus VC,
p = 0.011). None of the active treatments modified IL-10 se-
cretion (p ranging from0.479 to 0.948, data not shown). These
results indicate that the bioactive effects of the individual
treatments and combinations are largely selective for TNF-
and are therefore independent of NF-B. To verify this, an
NF-B luciferase assay was utilized. In cells transfected with
an NF-B reporter and stimulated with a subset of individ-
ual treatments or their combinations for 30 min prior to LPS
stimulation, none of the individual treatments or combina-
tions had any effect on LPS-induced NF-B reporter activity
(p ranging from 0.144 to 0.822, data not shown), confirming
that the effects on TNF- are independent of NF-B.
3.4 Post-transcriptional effects of flavonoids on
cytokine secretion
To determine if the effects of the bioactive treatments on LPS-
induced TNF- were transcriptional or post-transcriptional,
Table 4. Effect of treatments on TNF-mRNA expression
Treatment Average change in TNF-
mRNA from vehicle
control (% ± SD)
1 M
C3G ↑ 0.8 ± 13.0
P3G ↓ 7.0 ± 28.7
IVA ↓ 2.8 ± 62.7
IVA-glucuronide ↑ 17.1 ± 51.8
VA-glucuronide ↑ 6.3 ± 27.1
PCA-3-sulfate ↓ 1.3 ± 21.7
BA-sulfate ↓ 8.8 ± 33.2
Combo 9 ↑ 17.7 ± 36.0
Combo 10 ↑ 9.5 ± 28.7
Combo 13 ↓ 35.9 ± 65.8
Combo 16 ↑ 3.6 ± 56.1
VA ↑ 20.2 ± 55.5
PCA ↑ 17.5 ± 36.0
4HBA ↑ 44.5 ± 64.6
BA-glucuronide ↑ 23.8 ± 6.5*
PCA-3-glucuronide ↑ 25.9 ± 77.7
Treatments were added to THP-1 cells at a final concentration
of 1 M for 30 min prior to stimulation with 100 pg/mL LPS for
2 h. Data were normalized to GAPDH and compared with VC.
Data shown are averages of three independent experiments, each
carried out in technical duplicate. Analysis was performed by two-
tailed independent samples t-test.
cells were treated with the active treatments and TNF-
mRNA expression was examined by RT-qPCR. None of
the bioactive treatments significantly inhibited LPS-induced
TNF- mRNA expression (Table 4). Indeed, one of the com-
pounds of combination 13, BA-glucuronide, significantly
(p = 0.050) increased TNF-mRNA expression. In addition,
4HBA, which significantly inhibited LPS-induced IL-1 se-
cretion (p = 0.001), had no effect on IL-1mRNA expression
(p = 1.000).
4 Discussion
Flavonoids are perceived to be key components responsi-
ble for the observed health effects of fruits and vegetables
[30]. However, concentrations of individual flavonoid species
in the circulation, after “normal/habitual” dietary consump-
tion, are generally extremely low; many orders of magni-
tude below those observed to elicit cellular activity in in
vitro studies [19]. We hypothesized that the reported bio-
logical activities of flavonoids, following consumption, are
not a direct consequence of any individual flavonoid work-
ing in isolation, but result from a yet uncharacterized cu-
mulative activity of metabolites, working in combination.
We therefore established a screening model to test this hy-
pothesis, examining structurally similar flavonoids and some
of their shared metabolites in isolation, and in combina-
tions, as would potentially occur following dietary exposure.
Here, we observed some metabolites were more bioactive
C© 2015 The Authors. Molecular Nutrition & Food Research published by Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim www.mnf-journal.com
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than their precursor structures and that some combinations
of metabolites were more bioactive than their constituent
compounds.
The dietary flavonoids utilized in the present investi-
gation are found in abundance in our diets (https://www.
gov.uk/government/uploads/system/uploads/attachment_
data/file/193804/familyfood-2011report.pdf). Food sources
include onions and tea (quercetin), citrus (naringenin
and hesperetin), cocoa/chocolate, red wine and green tea
(epicatechin), and red and purple berries (peonidin and
cyanidin) [31, 32]. Reported levels of consumption vary
considerably, and depend on country and population/cohort
studied. In cohorts from the United States, Netherlands,
and Spain, dietary consumption has been estimated between
158 and 313 mg/day; representing levels for flavan-3-ols
between 32 and 158 mg/day, flavanones between 14 and
50 mg/day, flavonols between 13 and 21 mg/day, and
anthocyanins between 3 and 18 mg/day. However, these
estimates represent average consumption, and for many
flavonoids considerably higher dietary levels can be achieved
from a single serving of a flavonoid-rich food. For exam-
ple, anthocyanin concentrations in berries reach 100–700
mg/100 g and it is therefore not unrealistic to consume
as much as 250 mg in a single serving [33–35]. Despite
potentially high dietary intakes, levels of flavonoids in the
blood, postconsumption, are relatively low (generally well
below 10 M [16]). Rather than concentrating on dietary
flavonoids, the present study focused on the bioactivity of
the more physiologically relevant flavonoid metabolites, as
phenolic metabolites are reported to be the predominant
compounds in the systemic circulation [17, 19, 32, 36]. As
there is a substantial diversity of phenolic metabolites (or
ring-fission products) reported for the various flavonoids
[17, 32], we focused on phenolic acid conjugates common
to many flavonoid species, in addition to being found in
the habitual diet themselves. These include conjugates of
PCA, VA, and BA, which have been reported as phenolic
metabolites of berry anthocyanins [17, 19], cocoa flavan-3-ols
[22,23], and reported in our recent study of citrus flavanones
[37]. In addition, phenolic metabolites such as VA and ferulic
acid are found in the diet in grain and beer [38], while BA
conjugates can be derived from caffeic acid and ferulic acid,
which are found in red wine or derived from hydrolysable
tannins in the diet [32].
In the current study, we explored bioactivity across a con-
centration range of 0.1–10 M, as it represents the relative
serum/plasma concentration of flavonoids and their phenolic
metabolites reported in the literature. Serum/plasma concen-
trations of unmetabolized precursor flavonoids are generally
quite low, and reported in low to high nanomolar concentra-
tions (10–200 nM) [17, 19, 20, 32], aside from flavanols such
as epicatechin, which can reach micromolar concentrations
[20]. For example, following consumption of 500 mg of the
anthocyanin C3G, the phenolic metabolite VA was found to
peak at 1.8 M and persisted at levels of 1 M for up to 24
h. Similarly, total phenolic metabolites reached cumulative
concentrations of 10 M, in opposition to C3G that reached
a peak serum concentration of only 0.1 M [17, 19]. Compa-
rable individual and cumulative plasma concentrations have
been reported in studies feeding flavan-3-ols, flavanones, and
flavonols [22, 23, 39]. A 100 M treatment was also included
in the present study to represent a pharmacological dose to
reflect maximal responses observed in the literature. Inter-
estingly, doses of 1 M were consistently the most bioac-
tive of the concentrations tested (Table 2) and when looking
across the range of concentrations, U-shaped trends were of-
ten present. These bimodal effects are typical formany phyto-
chemicals [40] and in small dose ranges will appear as either
a U-shaped or inverse U-shaped dose–response, depending
on what part of the curve you capture. The bimodal actions
of quercetin have previously been reported in in vitro stud-
ies of basophil function [41]. In addition, bimodal increases
in flow-mediated dilatation were observed in healthy human
volunteers consuming various doses of a beverage rich in
blueberries [42], and similar observations were drawn from
a recent systematic review of randomized controlled trials
involving flavonoid interventions [43].
In the present study, we investigated the effect of the six
precursor flavonoids, 14 metabolites, and 29 combinations
on LPS-induced TNF- protein levels (Table 2). Initially, we
screened 49 treatments across four concentrations in trip-
licate, representing a total of 588 LPS-induced TNF- pro-
tein screens. Two precursor flavonoids (P3G and C3G) and
five metabolites (IVA, IVA-glucuronide, BA-sulfate, PCA-3-
sulfate, and VA-glucuronide) reduced TNF- secretion in
isolation (Table 2). The screen indicated that the flavonoid
metabolites appear more active than their precursor struc-
tures, suggesting that the metabolism of flavonoids increases
bioactivity in this model.
Four treatments comprising combinations of metabolites
(at equal molar ratios) containing: PCA and 4HBA; PCA,
4HBA, and VA; 4HBA, BA-glucuronide, and BA-sulfate; and
PCA and PCA-3-glucuronide significantly reduced TNF- se-
cretion at 1–10 M. Previously combination treatments of
chrysin and kaempferol have been reported to be active to-
ward LPS-stimulated RAW 264.7 cells, reducing nitric oxide,
prostaglandin E2, and TNF- levels [44], however this previ-
ous study focused on the effects of combinations of unme-
tabolized precursor flavonoids, which is less physiologically
relevant, as circulating monocytes are unlikely to be exposed
to high concentrations of unmetabolized flavonoids [17, 19],
particularly as precursor flavonoids are found at much lower
concentrations than their metabolites in the systemic circu-
lation [2, 20].
To allow a direct comparison between the treatments con-
taining combinations ofmetabolites and their individual con-
stituents, eachmetabolite was studied individually at the con-
centration it was present at in the active combination (e.g.
0.5 or 0.33 M) to establish if there effects were additive.
Here PCA, 4HBA, and VA were not active in isolation across
the dose ranges explored, suggesting additive effects of the
compounds when present together.
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Treatments that significantly modulated TNF- secretion
were further explored for their effect on IL-1, as with TNF-,
IL-1 is a critical mediator in inflammation where blockade
inhibits the progression of cardiovascular disease [8]. The
treatments that were previously indicated as bioactive in the
LPS-induced TNF- screen, had no effect on LPS-stimulated
IL-1 secretion, with the exception of 4HBA, which signifi-
cantly reduced IL-1 secretion by 49.6 ± 12.3% (p = 0.011).
PCA in isolation also showed a trend toward a reduction in IL-
1 secretion (16.8 ± 15.0%, p = 0.171). Studies by Wei et al.
and Monagas et al. have previously reported PCA decreas-
ing IL-1 secretion in LPS-stimulated murine lung tissue in
vivo, and 4HBA reducing IL-1 secretion in LPS-stimulated
peripheral mononuclear blood cells [45, 46]. These results
are interesting as both signaling pathways are regulated by
NF-B, and therefore a similar response would have been an-
ticipated if flavonoids and combinations regulated transcrip-
tion. In order to further explore the effect of the significant
bioactive treatments, TNF- and IL-1mRNAexpression and
NF-B activation were investigated. There was no effect on
mRNA levels, lending credence to the supposition of a post-
transcriptional mode of action. These results are similar to
data reported by other groups [47] showing quercetin to have
no effect on TNF- or IL-1mRNA levels in LPS-stimulated
THP-1 cells. In addition, none of the treatments affected NF-
B activation, which is similar to previous studies [47, 48],
where several flavonoids including naringenin, hesperetin,
and epicatechin (0.1–1 M) and quercetin (33 M) had no
effect on NF-B activation in astrocytes or J3774A.1 mouse
macrophages, respectively. In contrast, other studies [48, 49]
have shown NF-B inhibition following treatment with the
flavonoids apigenin and luteolin (30 M) in HEK293 cells
and kaempferol-3-O-glucoside (223 M) in J3774A.1 mouse
macrophages; however, none of these flavonoids were in-
vestigated in the present study. In addition, the effect on
NF-B activation was observed at 30–100 M concentrations
of the treatments, which is three- to ten-fold higher than
utilized in the present investigation. NF-B inhibition may
therefore require higher doses of flavonoids, which are likely
beyond that of which is physiologically relevant [50] following
habitual dietary intake. The effects of the active treatments
in the LPS-induced TNF- screen were also explored for
their ability to modulate IL-10 secretion as previously other
groups have shown changes in IL-10 levels [12, 13] follow-
ing treatment of PMA-differentiated THP-1 cells with quince
peel extract [12]. However, we saw no change in IL-10 pro-
tein secretion compared to the VC. This was also observed
in mice fed flavonoid-rich citrus peel extract for 6 wk [13].
IL-10 is also regulated by NF-B.
The protein, mRNA, and reporter assay data all indicate
that the flavonoids, metabolites, and combinations act on
TNF- after transcription. One possible target for future in-
vestigation is TNF- converting enzyme (TACE). TACE is
involved in the post-translation processing of TNF- protein
and its activity has been reported to be modulated by the
flavonoids rutin, orientin, and isoorietin [51, 52]. In contrast,
Catalan et al. showed that polyphenol-rich peanut extract had
no significant effect [53]; however, future studies should fo-
cus on the activity of flavonoid metabolites on TACE. Modu-
lation of TACE would provide an explanation for the different
effects between the cytokines, as TACE regulates the post-
translational processing of TNF- [54], but has no effect on
IL-1 or IL-10. IL-1 [55] is cleaved by caspase 1 to produce
its mature soluble form and IL-10 is not post-translationally
modified [56]. Another possible mechanism of action of the
flavonoids is inhibition of p38 MAP kinase. p38 MAP kinase
regulates TNF- protein but not mRNA expression [57] and
flavonoids, including procyanidins and epigallocatechin gal-
late, have previously been reported to inhibit LPS-induced
p38 MAP kinase phosphorylation in macrophages [58–60],
suggesting that this may be a potential mechanism for the
inhibitory effects of the flavonoid metabolites on TNF- pro-
tein but not mRNA expression. These potential mechanisms
warrant further investigation.
The present study is not without limitations, most no-
tably, the basic screening model utilized. Cell culture screen-
ingmethodologies utilizing a pharmacological stimulus such
as LPS are most responsive to pharmacologically active sub-
stances that have pronounced effects on protein and mRNA
expression. Titrating these stimuli to levels, which are more
appropriate for studying dietary phytochemical activity, pro-
duces less responsive systems, ultimately lowering the dy-
namic range of the assay, resulting in a larger variability be-
tween experiments. Therefore, standard screening models
may be less effective in identifying the activity of low con-
centrations of dietary phytochemicals, which was reflected
in the present study by the relatively low responses of the
treatments.
The present screen of flavonoid metabolites in isolation
and in combination, at low micromolar concentrations, is a
novel design and provides an important contribution to the
field, as it aims to explore the activity of a group of physiolog-
ically relevant phytochemical metabolites at appropriate con-
centrations. The study of complex mixtures of metabolites,
in addition to utilizing pure synthesized metabolites is also
quite unique. However, as there is a substantially high day-
to-day variation in dietary flavonoid consumption between
individuals, and enormous interindividual variation reported
for the absorption, distribution, metabolism, and elimina-
tion of flavonoids [17,19], designing a treatment that entirely
mimics plasma composition is unrealistic. Because of this ac-
tuality, we selected amore practical approach of exploring the
activity of a number of simple and complex mixtures of struc-
turally similar flavonoids and metabolites across a concen-
tration range, in order to gain insight into structure–activity
relationships and additive and/or synergistic activities. As the
concentrations of each individual analyte would differ with
diet and individual, it was also practical to use equal concen-
trations of the analytes in the mixtures. Most in vitro studies
in the past have investigated the actions of supraphysiological
concentrations of precursor flavonoids in isolation, or using
crude fruit or serum extracts. Here, our screen has revealed
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possible modes of action of flavonoid metabolites, however,
further work is needed to fully ascertain the mechanisms of
action. Interestingly, the greatest activities observed appeared
to be at the lowest concentrations investigated and appeared
nonlinear, which could suggest high-dose interventions may
not be necessary for prevention or disease risk-reduction. Ul-
timately, the present study suggests that the health benefits
observed in epidemiological studies, which have been accred-
ited to flavonoid consumption,may be the result of the activity
of complex combinations of flavonoids and their metabolites,
as found in the systemic circulation following normal dietary
consumption.
In conclusion, we have shown that some metabolites
of flavonoids individually and in combination appear more
bioactive then their precursor flavonoids, at equivalent con-
centrations. In time, these data may help establish appro-
priate combinations of flavonoid-rich foods for utilization
in animal and human trials exploring dietary strategies for
cardio-protection.
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